IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent	Application of)	Attorney Docket No.: SOEI0009
Jun KASH	IMURA et al.)	Confirmation No. 2759
Serial No.:	10/715,125)	Group Art Unit: 1761
Filed: Nov	ember 18, 2003)	Examiner: Unassigned
LEV BOI	OUCER OF BLOOD GLUCOSE TEL INCREASE REDUCER OF OY FAT ACCUMULATION AND OD MATERIAL))))	Date: May 7, 2007

INFORMATION DISCLOSURE STATEMENT

MAIL STOP: Amendment

United States Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, this Information Disclosure Statement in connection with the above-identified application is being filed in accordance with 37 C.F.R. §1.97(b):

- within three months of the filing date of this application (not a C.P.A.);
 within three months of the date of entry of the National Stage;
- X before the mailing date of a first Office Action on the merits; or
- before the mailing of a first Office Action on the merits of, after the filing of a Request for Continued Examination (RCE) under §1.114.

Foreign Patent Document 1 relates to a special drink or food. Non-Patent Literature

-1-

Document 1 is the Office Action in which is cited. Their relevance is believed to be clear from the abstract of the disclosure. Accordingly, no further comment with regard to the disclosures of these documents is believed to be required.

The Office Action was mailed on February 6, 2007, less than three months prior to the filing of this Information Disclosure Statement. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

It is respectfully requested that the attached documents be considered and officially cited, and that the Examiner initial a copy of Forms PTO/SB/08A and PTO/SB/08B, and return them to the undersigned to indicate that the documents have been considered.

It is believed that the present Information Disclosure Statement complies with the requirements of 37 C.F.R. §§ 1.97-8, but should the filing of this paper necessitate a fee, the Director is hereby authorized to charge the necessary fee to Deposit Account No. 50-1281.

Respectfully submitted,

GRIFFIN & SZIPL, PC

Joerg-Uwe Szipl

Registration No. 31,799

GRIFFIN & SZIPL, PC Suite PH-1 2300 Ninth Street, South Arlington, VA 22204 Telephone: (703) 979-5700 Facsimile: (703) 979-7429

E-mail: gands@szipl.com

Customer No.: 24203